Physician profile
Donald D Asante
NPI 1104068220
$2,327.72
in general payments reported to CMS, 2019-2025
27 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.05 · 2020: $541 · 2021: $509 · 2022: $371 · 2023: $106 · 2024: $143 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $416.30 | 2020-2025 | Trelegy Ellipta |
| Pfizer INC. | $338.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $239.78 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $231.56 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $183.21 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $166.55 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Paratek Pharmaceuticals, INC. | $145.33 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $135.18 | 2020 | |
| Lilly USA, LLC | $61.56 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $48.15 | 2022-2023 | |
| Amgen INC. | $36.14 | 2025 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $31.52 | 2025 | Zoryve |
| Eisai INC. | $31.25 | 2021 | |
| Amarin Pharma, INC. | $29.85 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.39 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.41 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.39 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.65 | 2024 | Nuedexta |
| Phathom Pharmaceuticals, INC. | $18.35 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $17.29 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $16.51 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $16.44 | 2021 | |
| Medtronic, INC. | $14.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.69 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.36 | 2021 | |
| Hikma Pharmaceuticals USA | $13.36 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Asante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.